

Imaging as a Biomarker: Standards for Change Measurements in Therapy

Breakout Area 3: MRI, MRS, DCE and Diffusion MRI:
What can be measured over time?

Day 1: Summary of “Big Picture Roadmapping
– The What by When?”
Near, Mid and Long-Term Issues

Chair

Jeffrey L. Evelhoch, PhD
Director of Medical Sciences Imaging
Amgen, Inc.

A U.S. Measurement System Workshop
September 14-15, 2006
National Institute of Standards and Technology

Breakout Area 3: MRI, MRS, DCE and Diffusion MRI:
What can be measured over time?
Near-Term 1-3 Years

1. *State Innovation or Challenge: Phantoms (head & body)*
 - ☐ Impact of Success: uniformity across sites & time
 - ☐ Technical Barriers: specifications
 - ☐ Key Players:
2. *State Innovation or Challenge: Account for upgrades*
 - ☐ Impact of Success: less data lost
 - ☐ Technical Barriers: specifications, vendor buy-in
 - ☐ Key Players:
3. *State Innovation or Challenge: Data analysis validation*
 - ☐ Impact of Success: results comparable
 - ☐ Technical Barriers: data for comparison (real and/or digital), ground truth
 - ☐ Key Players:

Breakout Area 3: MRI, MRS, DCE and Diffusion MRI: What can be measured over time?

Mid-Term 3-5 Years

1. *State Innovation or Challenge: Clinical trial packages*

- ☐ Impact of Success: Qualified sites, account for upgrade impact
- ☐ Technical Barriers: specifications, vendor buy-in, \$\$\$
- ☐ Key Players:

2. *State Innovation or Challenge: k-space data*

- ☐ Impact of Success: flexibility, uniformity, quality
- ☐ Technical Barriers: define format, user friendly, vendor buy-in, size
- ☐ Key Players: DICOM

3. *State Innovation or Challenge:*

- ☐ Impact of Success:
- ☐ Technical Barriers:
- ☐ Key Players: